論文・技術情報追加のお知らせ

1. Real-world safety profile of bisoprolol: signal detection and demographic stratification using the FAERS database.

ビソプロロールで新規シグナル、嚥下痙攣・掌蹠角化症確認

対象DB：EudraVigilance,FAERS

2. Mining safety signals of letermovir drug combinations: real-world pharmacovigilance analysis.

レテルモビルで心毒性とDDIで肝腎毒性増加

対象DB：FAERS

3. Desflurane Safety Revisited: A Pharmacovigilance Study Detecting Potential Safety Signals from FAERS Data.

デスフルランで重篤AEシグナル、循環・呼吸系注意

対象DB：FAERS

4. Drug-induced agranulocytosis: a disproportionality analysis and umbrella review.

DIAは抗がん薬中心、高齢・体重異常で高リスク

対象DB：FAERS

5. Safety profiles of dasatinib in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database.

小児ダサチニブで新規AEシグナル、出血性腸炎等確認

対象DB：FAERS

6. Information pharmacists assist in the construction of GLP-1RA prescription review rules in a tertiary hospital in China.

GLP-1RA処方基準導入で適正化と安全性向上

対象DB：FAERS

7. Postmarketing analysis of sotatercept: identifying serious unlabelled events.

ソタテルセプトで出血含む新規AEシグナル確認

対象DB：EudraVigilance,FAERS

8. Identifying Pediatric Drug Safety Knowledge Gaps: An Integrated Approach Leveraging Real-World Data, a Biomedical Knowledge Base, and Postmarketing Surveillance Data.

小児でベンゾナタート安全性乏しく重篤AE多発

対象DB：FAERS

9. Adverse events associated with Lutetium-177-PSMA-617 (Pluvicto((R))) in advanced prostate cancer: a disproportionality analysis based on the fda's adverse event reporting system (FAERS).

プルビクトで有害事象多数、早期神経症状に注意

対象DB：FAERS

10. Real-world adverse event analysis of Adagrasib: Insights from the FAERS database.

アダグラシブで新規AEシグナル、皮膚色素沈着・痙攣など確認

対象DB：FAERS

11. Characterisation of systemic lupus erythematosus associated with immune checkpoint inhibitors: a pharmacovigilance study using FAERS database.

ICIでSLEシグナル、女性・PD-1で高リスク

対象DB：FAERS

12. Comprehensive analysis of sparsentan-related adverse events: latest insights from VigiAccess and FAERS.

スパルセンタンで軽微AE多いが重篤例も存在

対象DB：FAERS

13. Oral bowel cleansers and ischemic colitis risk: A real-world disproportionality analysis.

ビサコジルでIC強シグナル、PEGでも重篤例報告

対象DB：FAERS

14. Multi-database pharmacovigilance assessment of GLP-1 receptor agonist-related ophthalmic risks using advanced signal detection in FAERS and vigibase.

GLP-1作動薬で眼毒性シグナル、特にセマのNAION強い

対象DB：FAERS,VigiBase

15. Pharmacovigilance assessment of drug-induced aplastic anemia: analysis of the FDA adverse event reporting system.

FAERSで再生不良性貧血の薬剤リスク同定、予測モデル構築

対象DB：FAERS

16. Safety assessment of gemtuzumab ozogamicin: real-world adverse event analysis based on the FDA Adverse Event Reporting System.

ゲムツマブでVODシグナル、新規COP等も検出

対象DB：FAERS

17. Auditory system adverse events with sacubitril/valsartan: an active-comparator restricted disproportionality analysis using the FDA adverse event reporting system database.

サクビトリル/バルサルタンで聴覚前庭障害リスク増示唆

対象DB：FAERS

18. Psychiatric disorders associated with newer antiseizure medications: A real-world disproportionality analysis of FDA adverse event reporting system.

新規抗てんかん薬で精神障害リスク高、早期発現注意

対象DB：FAERS

19. Improving Large Language Models for Clinical Named Entity Recognition via Prompt Engineering.

臨床NERでGPT改善、特化プロンプトで性能向上

対象DB：FAERS,VAERS

20. Evaluation of Intraocular Anti-vascular Endothelial Growth Factor (VEGF) Drug-Associated Adverse Events Using Spontaneous Reporting Databases.

抗VEGFで脳梗塞発現、IVRがIVAより早期傾向

対象DB：JADER

21. Changes in the trend and quality of adverse drug reaction reports in the Japanese Adverse Drug Event Report database and the impact of COVID-19-related reports.

COVID-19でJADER報告質一時向上、傾向変化

対象DB：JADER

22. Analysis of drug-drug interactions in spontaneous adverse drug reaction reports from EudraVigilance focusing on psychiatric drugs and somatic medication.

精神薬と身体薬の相互作用を自発報告で解析

対象DB：EudraVigilance

23. Antibiomania: A Systematic Review of Clarithromycin-Associated Manic Episodes.

クラリスロマイシンで稀な躁症、中止で回復

対象DB：EudraVigilance

24. Blinded by the drug? A vigilyze signal linking semaglutide to NAION.

セマグルチドで稀なNAION報告、早期対応促す

対象DB：VigiBase

25. Difference in outcome event coverage between insurance-based and hospital-based databases: a methodological study of diabetes drug use and cardiovascular events in Japan.

保険より病院DBで事象捕捉率低め、HR差あり

対象DB：DPC

26. Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study.

ダロルタミドで継続長く進行遅延傾向

対象DB：MDV

27. Traumatic Brain Injury and Risk of Amyotrophic Lateral Sclerosis.

TBI後2年でALSリスク上昇、以後は不明確

対象DB：CPRD

28. Ethnic inequities in childhood influenza vaccination coverage in England 2013-2021: An observational cohort study.

幼児インフル接種低く、民族間格差拡大傾向

対象DB：CPRD

29. Risk of self-harm and the use of leukotriene receptor antagonists and inhaled corticosteroids: a population-based study.

LTRA/ICSで自傷リスク増加は支持されず

対象DB：CPRD

30. National roll-out of social prescribing in England's primary care system: a longitudinal observational study using Clinical Practice Research Datalink data.

英国でソーシャル処方急拡大、格差残るが拒否減少

対象DB：CPRD

31. Ocrelizumab-induced neutropenia: severity, recurrence, and management. A French national pharmacovigilance study.

オクレリズマブで遅発性好中球減少、再発25%程度

対象DB：FPVD

32. Work productivity by diseases diagnosed among workers: a study using large-scale claims data and survey data of workers in Japan.

精神疾患・頭痛等で労働生産性低下が顕著

対象DB：DeSC

33. The provision of cognitive behavioral therapy in Japan: an analysis using insurance claims data.

日本でCBT保険利用低く、月1超の間隔が多い

対象DB：DeSC